Isomorphic Labs
PulseAugur coverage of Isomorphic Labs — every cluster mentioning Isomorphic Labs across labs, papers, and developer communities, ranked by signal.
- founded by Alphabet Inc. 90%
- spun off from Eli Lilly and Company 90%
- spun off from Novartis 90%
- founded Novartis 90%
- invested by Thrive Capital 90%
- spun off from John Michael Jumper 90%
- affiliated with Alphabet Inc. 70%
- competes with Alphabet Inc. 70%
- employed by John Michael Jumper 70%
- uses Novartis 70%
- affiliated with Eli Lilly and Company 70%
- founded by Jeff Dean 70%
- 2026-07-17 product_launch Isomorphic Labs launched its Drug Design Engine, a new platform for drug discovery. source
- 2026-06-11 product_launch Isomorphic Labs is developing advanced protein modeling tools to accelerate AI-driven drug discovery. source
- 2026-05-27 funding Isomorphic Labs secured $2.1 billion in Series B funding led by Thrive Capital to accelerate its AI drug discovery efforts. source
- 2026-05-13 funding Isomorphic Labs secured $2.1 billion in Series B funding. source
- 2026-05-12 funding Isomorphic Labs secured $2.1 billion in Series B funding.
- 2026-05-12 funding Isomorphic Labs raised $2.1 billion in a Series B funding round.
- 2026-04-24 funding Isomorphic Labs closed a $2.1 billion Series B funding round led by Thrive Capital. source
8 day(s) with sentiment data
-
Demis Hassabis reportedly considering reduced role at Google to focus on Isomorphic Labs
Demis Hassabis, Google's Chief Scientist, is reportedly considering a reduced role or departure from the company. Speculation suggests he wishes to focus more on Isomorphic Labs, a company he chairs. There is also conje…
-
Demis Hassabis's Google DeepMind Role Shift Sparks Promotion vs. Demotion Debate
Demis Hassabis has transitioned from CEO of Google DeepMind to Chief Scientist, sparking debate about whether this move was a promotion or a demotion. Supporters suggest it allows him to focus more on research and Isomo…
-
Google reshuffles AI leadership: Hassabis to Alphabet chair, Dean departs
Google has undergone a significant restructuring of its AI leadership. Demis Hassabis is transitioning to the role of Alphabet chair and chief scientist, while still overseeing Isomorphic Labs. Concurrently, Jeff Dean, …
-
Google reshapes AI leadership: Hassabis moves up, Dean departs for startup
Google has undergone a significant AI leadership shake-up, with Demis Hassabis stepping down from his daily operational role at Google DeepMind to become Alphabet's chief scientist and chair of Google DeepMind. Jeff Dea…
-
Google DeepMind CEO Demis Hassabis steps down; Jeff Dean departs for AI startup
Google DeepMind CEO Demis Hassabis is stepping down from his day-to-day management role to become the chairman of Google DeepMind and chief scientist for Alphabet. Koray Kavukcuoglu, the current CTO, will take over dail…
-
OpenAI slashes GPT-5.6 prices; AI lab staff call for development slowdown · 2 sources tracked
OpenAI has significantly reduced prices for its GPT-5.6 Luna model, cutting costs by 80% just weeks after its launch, attributing the decrease to internal efficiency gains. Meanwhile, a group of employees from major AI …
-
Google DeepMind disbands AlphaFold team; Nobel laureates join Anthropic
Google DeepMind has disbanded its renowned AlphaFold team, which was instrumental in solving protein structure prediction and included Nobel laureates. While Google states the team's expertise is being redirected to bro…
-
Google shutters Nobel-winning AlphaFold AI project to focus on Gemini
Google has reportedly shut down its Nobel Prize-winning AlphaFold project, reassigning its team members to focus on Gemini-related initiatives. AlphaFold, an AI program developed by Google DeepMind, revolutionized prote…
-
Isomorphic Labs unveils new engine surpassing AlphaFold for drug design
Isomorphic Labs has unveiled its Drug Design Engine (IsoDDE), a computational platform designed to advance drug discovery beyond the capabilities of AlphaFold. This new engine demonstrates superior accuracy in predictin…
-
Ex-OpenAI Researcher's AI Drug Startup Nears $2B Valuation
A former OpenAI researcher, Miles Wang, has left the company to co-found an AI drug discovery startup, which is reportedly in talks for a $200 million funding round at a $2 billion valuation. This move highlights a grow…
-
Google DeepMind and Isomorphic Labs launch bioresilience initiative
Google DeepMind and Isomorphic Labs have launched a bioresilience initiative aimed at mitigating the misuse of advanced AI in biological contexts while simultaneously enhancing capabilities for outbreak detection and re…
-
Google DeepMind partners with Isomorphic Labs on AI for biosecurity
Google DeepMind is collaborating with Isomorphic Labs to address the evolving biosecurity landscape. The partnership aims to develop proactive defenses for global health by leveraging advanced AI technologies. This init…
-
Google DeepMind and Isomorphic Labs partner on AI for bioresilience
Google DeepMind and Isomorphic Labs are collaborating on a bioresilience program to leverage AI for preventing, detecting, and responding to biological threats. Their approach involves ensuring AI models are not misused…
-
OpenAI Researcher Eyes $2B Valuation for AI Drug Discovery Startup
Miles Wang, a researcher from OpenAI, is reportedly in discussions to launch a new startup focused on AI-driven drug discovery. The venture is aiming to secure approximately $200 million in funding at a valuation of $2 …
-
Anthropic launches Claude Science, plans to develop its own drugs
Anthropic has introduced Claude Science, a new research environment designed to accelerate scientific discovery by integrating tools, datasets, and visualization capabilities. Beyond providing AI tools for the life scie…
-
Eli Lilly invests $40M in AI drug firm Absci for baldness treatment
Eli Lilly has invested $40 million in Absci, a generative AI drug discovery company, as part of a larger $100 million stock offering. Absci utilized AI to design ABS-201, an injectable antibody targeting a hormone recep…
-
Google DeepMind Loses Top AI Talent to OpenAI and Anthropic
Several high-profile researchers have departed Google DeepMind, sparking concerns about Alphabet's competitive edge in the AI race. Notable exits include Noam Shazeer, who is joining OpenAI after previously criticizing …
-
Alphabet's algorithm crash highlights AI's lack of oversight and market impact
An algorithm developed by Alphabet, designed for "dark engagement" and the propagation of "fake narratives," has demonstrated a lack of human oversight. This system incorrectly flagged real economic data as conspiracy t…
-
AI-DNA startup Radical Numerics raises $50M seed funding
Radical Numerics, a startup founded by researchers who developed AI models for DNA generation, has secured $50 million in seed funding. The company aims to revolutionize biology by teaching AI to understand and generate…
-
Isomorphic Labs advances AI drug discovery with new tools
Isomorphic Labs, a spinout from Google DeepMind, is heavily investing in AI for drug discovery. The company is developing sophisticated protein modeling tools, leveraging Nobel Prize-winning research. These advancements…